Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 16/20 | 0.55 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241793 | 1.00 | HCRTR1 (0.55) | HCRTR1HCRTR2ALDH1A1MAPTLMNA | |
| SCHEMBL8224513 | 0.89 | HCRTR1 (0.51) | HCRTR1HCRTR2ALDH1A1MAPTLMNA | |
| SCHEMBL4246850 | 0.89 | HCRTR1 (0.51) | HCRTR1HCRTR2ALDH1A1MAPTLMNA | |
| SCHEMBL4246856 | 0.89 | HCRTR1 (0.51) | HCRTR1HCRTR2ALDH1A1MAPTLMNA | |
| SCHEMBL8416035 | 0.82 | JAK3 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL1597257 | 0.80 | HCRTR1 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL1598301 | 0.80 | HCRTR1 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL8224540 | 0.80 | HCRTR1 (0.52) | HCRTR1HCRTR2ALDH1A1MAPTLMNA | |
| SCHEMBL1597243 | 0.80 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL1597246 | 0.80 | HCRTR1 (0.52) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | claimed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | claimed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | HCRTR1 1/4885HCRTR2 2/4885ALDH1A1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.